Efficacy of Electroacupuncture in Carpal Tunnel Syndrome

January 30, 2022 updated by: Dr Kassiani Theodoraki, Aretaieion University Hospital

Efficacy of Electroacupuncture in Carpal Tunnel Syndrome: a Clinical, Electrophysiologic and Ultrasonographic Study

The aim of this clinical study is to assess the effectiveness of electroacupuncture in reducing the severity of symptoms, in improving limb function, in improving the aesthetic and motor conduction of the median nerve and in reducing its cross-sectional area at the inlet of the carpal tunnel in patients with carpal tunnel syndrome. All upper extremities diagnosed with carpal tunnel syndrome will be treated with electroacupuncture for 8 sessions. Clinical, electrophysiological and ultrasonography outcome measures will be evaluated before and after the intervention, to assess the result.

Study Overview

Detailed Description

Carpal tunnel syndrome (CTS) is the most common mononeuritis, with a significant burden on both patients and public health. For mild and moderate cases, conservative methods, including immobilization, corticosteroid injections, oral medications and physical therapy have been suggested as appropriate treatments, with mixed results. Acupuncture and related therapies has been used worldwide over the last few years in the management of CTS, with generally positive results. However, more studies will be needed to assess the role of acupuncture as an independent therapeutic modality to CTS.

This is a clinical study that will be conducted in the pain clinic at the department of Anaesthesiology of Aretaieion University Hospital as well as in the Laboratory of Musculoskeletal Physiotherapy of University of West Attica, with which there is a cooperation agreement. All recruited participants will be treated with the same acupuncture protocol at the limb that will be diagnosed with carpal tunnel syndrome. If the patients are diagnosed with bilateral CTS, both wrists will be treated. Clinical, electrophysiological and ultrasonography outcomes will be measured before and after the intervention.

In order to record the possible influence of psychosomatic characteristics, the Greek version of the Hospital Anxiety & Depression (HAD) Scale will be used before the treatment. As a result the anxiety and the depression of the participants will be quantified with a simple clinical tool.

All participants will accept 8 sessions of electroacupuncture, 2 days a week for 1 month by experienced physicians.

All participants in the study will be evaluated 3-7 days before and 3-7 days after the treatment protocol with clinical, electrophysiological and ultrasonographical outcome measures. In patients with bilateral symptoms, each limb will be assessed separately.

Study Type

Interventional

Enrollment (Actual)

25

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Athens, Greece, 11528
        • Pain Clinic of Aretaieion University Hospital
      • Athens, Greece, 12243
        • Laboratory of Musculoskeletal Physiotherapy of University of West Attica

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 80 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • paraesthesia, numbness, pain in the area of distribution of the median nerve
  • worsening of symptoms at night or with repeated movements of the wrist
  • aesthetic or/and motor deficits in the area of distribution of the median nerve
  • Median sensory nerve conduction velocity (SNCV), first digit to wrist <42 m/s
  • Median distal motor latency (DML), wrist to thenar eminence >4 ms.
  • Difference between the median and radial sensory latencies to the thumb ≥ 0,5 ms.
  • Median palmar peak latency (PL)> 2,2 ms and in comparison to ulnar palmar peak latency ≥ 0,4 ms.
  • Median versus Ulnar - Lumbrical - Interossei studies (Difference between the median 2nd lumbrical & ulnar 1st palmar interosseous distal latency, >0,5 ms).

Exclusion Criteria:

  • age<18 years
  • absence of the above electrophysiological criteria
  • diagnosis of another disease during the electrophysiological test
  • patients with severe carpal tunnel syndrome to be operated on
  • thenar muscle atrophy
  • previous carpal tunnel release surgery
  • local steroid injections in the last 3 months
  • clinical active rheumatic disease
  • diabetic polyneuropathy
  • alcoholism
  • neurological disease affecting the upper extremity (stroke, multiple sclerosis, amyotrophic lateral sclerosis, cervical radiculopathy, polyneuropathy)
  • contraindications to electroacupuncture: pacemaker, epilepsy, skin disorders in the upper extremities
  • no consent to the study
  • language or communications barriers

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: NA
  • Interventional Model: SINGLE_GROUP
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
OTHER: upper extremity diagnosed with carpal tunnel syndrome
8 sessions of electroacupuncture, 2 days a week for 1 month by experienced physicians
All participants will accept 8 sessions of electroacupuncture, 2 days a week for 1 month by experienced physicians. Acupuncture sterile disposable needles 0,25x 0,25 mm will be inserted for 20 minutes at specific acupuncture points to all patients. Electrical stimulation will be applied at specific acupuncture points for 20 minutes.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
change from baseline in Symptom Severity Scale (SSS) of -the Greek- Boston carpal tunnel questionnaire (BCTQ)
Time Frame: 3-7 days after the treatment protocol
The Boston carpal tunnel questionnaire (BCTQ) is an easy, disease-specific measurement of self-reported symptom severity and functional status for carpal tunnel syndrome (CTS). It has two distinct scales, the Symptom Severity Scale (SSS) which has 11 questions and the Functional Status Scale (FSS) containing 8 questions. Each scale using a five-point rating score generates a final score which ranges from 1 to 5, with the higher indicating greater disability. We will use the Greek version of the BCTQ, which had been examined for reliability and validity and responsiveness before and after the intervention.
3-7 days after the treatment protocol

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
change from baseline in Functional Status Scale (FSS) of -the Greek- Boston carpal tunnel questionnaire (BCTQ)
Time Frame: 3-7 days after the treatment protocol
The Boston carpal tunnel questionnaire (BCTQ) is an easy, disease-specific measurement of self-reported symptom severity and functional status for carpal tunnel syndrome (CTS). It has two distinct scales, the Symptom Severity Scale (SSS) which has 11 questions and the Functional Status Scale (FSS) containing 8 questions. Each scale using a five-point rating score generates a final score which ranges from 1 to 5, with the higher indicating greater disability. We will use the Greek version of the BCTQ, which had been examined for reliability and validity and responsiveness before and after the intervention.
3-7 days after the treatment protocol
change from baseline in Visual Analogue Scale (VAS)
Time Frame: 3-7 days after the treatment protocol
The Visual Analogue Scale (VAS) will be used to measure the severity of pain induced by carpal tunnel syndrome before and after the intervention. Zero is the minimum score and ten is the maximum score for pain.
3-7 days after the treatment protocol
change from baseline in median sensory nerve conduction velocity (SNCV)
Time Frame: 3-7 days after the treatment protocol
Change from baseline of electrophysiological parameters will be assessed after the treatment by using Keypoint electromyography
3-7 days after the treatment protocol
change from baseline in median distal motor latency (DML)
Time Frame: 3-7 days after the treatment protocol
Change from baseline of electrophysiological parameters will be assessed after the treatment by using Keypoint electromyography
3-7 days after the treatment protocol
change from baseline in median sensory nerve action potential (SNAP)
Time Frame: 3-7 days after the treatment protocol
Change from baseline of electrophysiological parameters will be assessed after the treatment by using Keypoint electromyography
3-7 days after the treatment protocol
change from baseline in cross sectional area of the median nerve
Time Frame: 3-7 days after the treatment protocol
The Cross sectional area (CSA) of the median nerve at the inlet of carpal tunnel (at the level of pisiform and scaphoid bone) will be measured before and after treatment by the Sonosite edge Ultrasound machine (6 MHz- 15 MHz linear probe)
3-7 days after the treatment protocol
adverse events
Time Frame: 3-7 days after the treatment protocol
number of patients who develop adverse events
3-7 days after the treatment protocol
number of patients who require medication throughout treatment
Time Frame: 3-7 days after the treatment protocol
need for additional medication throughout treatment
3-7 days after the treatment protocol
change from baseline in distal sensory latency (DSL) of the median nerve
Time Frame: 3-7 days after the treatment protocol
Change from baseline of electrophysiological parameters will be assessed after the treatment by using Keypoint electromyography
3-7 days after the treatment protocol

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

July 1, 2020

Primary Completion (ACTUAL)

December 31, 2021

Study Completion (ACTUAL)

December 31, 2021

Study Registration Dates

First Submitted

October 18, 2020

First Submitted That Met QC Criteria

October 22, 2020

First Posted (ACTUAL)

October 26, 2020

Study Record Updates

Last Update Posted (ACTUAL)

February 1, 2022

Last Update Submitted That Met QC Criteria

January 30, 2022

Last Verified

January 1, 2022

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pain

Clinical Trials on 8 sessions of electroacupuncture to the upper limb with carpal tunnel syndrome

3
Subscribe